K-Bio Value Report

Decoding the Future of K-Bio Value

Navigating the Quantum Leap of K-Bio

  • Welcome to K-Bio value analysis web site

    Welcome to K-Bio value analysis web site

    K-Bio Industry Overview: 2025 Performance and 2026 Outlook In 2025, the K-Bio industry demonstrated solid growth, driven by expanding global demand for biopharmaceuticals and the strengthening competitiveness of Korean biotech companies. Exports of biopharmaceutical products increased steadily, supported by large-scale biologics manufacturing, growing biosimilar penetration, and continued progress in innovative…

  • Anti-idiotypic Regulatory T Cell Theory (Research Introduction)

    1. Summary of Key Content Background and Research Gap Immune tolerance — the suppression of excessive immune responses against self- and foreign antigens — is the central mechanism preventing autoimmune and allergic diseases. Regulatory T cells (Treg cells) are the primary orchestrators of this tolerance. When their number or function…

● Latest Articles

  • OliX Pharmaceuticals

    OliX Pharmaceuticals is moving beyond the liver to own the “non-liver” RNAi delivery platforms of the future. Its strategy is focused on cp-asiRNA for local…

  • Chong Kun Dang (CKD)

    Technical Analysis: The Power of Open Innovation & Commercialization Chong Kun Dang has solidified its position by expertly blending proprietary drug development with strategic in-licensing…

  • Celltrion vs. Samsung Bioepis: Which One Holds the Global Edge?

    For everyday investors, choosing between South Korea’s two biotech titans—Celltrion and Samsung Bioepis—often feels like choosing between a “pioneering architect” and a “master manufacturer.” As…

  • Hanmi Pharm

    Hanmi Pharm

    1. LAPSCOVERY™: The Verified Bio-Platform Hanmi’s core technical advantage is the LAPSCOVERY™ (Long-Acting Protein/Peptide Discovery) technology. LAPSCOVERYTM Long Acting Protein / Peptide Discovery Platform Technology Overview  Biologics have…

● About Me

“PhD Scientist & 10-Year K-Bio Investor: Decoding the Life Science of Value.”

I am a Life Sciences PhD with industrial R&D experience across mAbs, BsAbs, ADCs, Vaccines, Cell/Gene Therapy and Medical Devices. By merging my technical expertise with over a decade of active investment in the K-Bio market, I translate complex innovation into clear, data-driven insights to help you find the real value behind the jargon.

● 최근 글